See all
Latest Trade Alerts
Sarepta's Risks Shouldn't Be Ignored
Written by:
Nathan Sadeghi-Nejad
08/21/12 - 7:00 AM EDT
Tickers in this article:
SRPT GSK
More Headlines
Biotech Stock Mailbag: Vical, Sangamo, Spectrum Pharma
ASCO '13 Preview: Oncothyreon's Failed Lung Cancer Vaccine
ASCO '13 Preview: Roche's Next-Gen Rituxan Steps Up
Aveo Screwed Up but Its Kidney Cancer Drug Is Real
The Deal: Bain, TPG Get Windfall With Quintiles IPO
« first
‹ previous
1
2
3